Plus   Neg

Stock Alert: Athenex Up 13% As FDA Grants Priority Review For NDA Of Breast Cancer Drug

Shares of Athenex, Inc. (ATNX) are currently gaining over 13% on Tuesday morning after the company announced that FDA accepted its NDA filing for oral paclitaxel and encequidar in metastatic breast cancer with priority review.

ATNX is currently trading at $13.00, up $1.51 or 13.14%, on the Nasdaq.

Athenex said FDA has granted a priority review for its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

The FDA grants Priority Review to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

The FDA has set a target action date of February 28, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Aviation Administration issued first airworthiness certificate for one of the new Boeing 737 Max jets on Monday since the aircraft was grounded worldwide in March 2019 following two crashes that killed 364 people, media reports quoting a FAA spokesman said. Amazon Web Services or AWS, the cloud division of Amazon, announced the launch of new virtual computing instances, known as EC2 Mac instances, for Apple app developers. The new Mac instances will help AWS users to run Apple's macOS operating system on Amazon Elastic Compute Cloud or Amazon EC2. EC2 Mac instances will allow customers to run on-demand macOS workloads in the AWS cloud. You stand a chance to win a free mouth-watering and saucy McRib Sandwich from McDonald's, that will be reintroduced on December 2 after being off its menu since 2012. But there is a condition. McDonald's will be giving out a FREE McRib to the first 10,000 entries that post a picture of their cleanly-shaven or baby-smooth face on their public Twitter or public Instagram profile.
Follow RTT